How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A First-in-Human Phase 1, Open-label, Two-stage, Randomized Trial to Assess the Safety, Tolerability, and Biodistribution of [177Lu]Lu-ABY-271 in Tumors and Critical Organs in Subjects With HER2-positive Metastatic Breast Cancer
Description:
This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.
Sponsor:
Affibody
Contacts:
Affibody ABaby-271-101@affibody.se
46859883800
Government Study Link:
NCT07081555 - Click here to see study onClinicalTrials.gov
[177Lu]Lu-ABY-271
Isotope(s):
Target(s):
- HER2
Chelator: DOTA
